Exin Therapeutics
Winter 2025 · Active
AI drug discovery platform for neurotherapeutics
Location: San Francisco, US
Founded: 2024
Team size: 3
About
Founders
Gabriel Ocana SanteroFounder
Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
Ivan LazarteFounder
Experience in interdisciplinary research spanning Physics, Engineering and Neuroscience. DPhil in Physiology, Anatomy, and Genetics, focusing on molecular to systems level brain development and function, complemented by computational biophysical modeling.
Marko TvrdicFounder
Cofounder & COO @ Exin Therapeutics. Worked across analysis levels in bio – from molecules to complex behavior. Previously, I worked on retinal and circadian rhythm disorders, neurodevelopment, and systems and comp neuro, with a small stint in venture. Oxford MSc + PhD (on leave to build Exin).